Market Moves
BlueWind Medical raises $47.8 million to scale Revi as the implantable tibial neuromodulation category separates from sacral nerve stimulation
BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.